Literature DB >> 17259939

Biomarker development, commercialization, and regulation: individualization of medicine lost in translation.

C Wilson, S Schulz, S A Waldman.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17259939     DOI： 10.1038/sj.clpt.6100088

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  16 in total

1.  Molecular staging estimates occult tumor burden in colorectal cancer.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

2.  Towards consensus practices to qualify safety biomarkers for use in early drug development.

Authors:  Frank D Sistare; Frank Dieterle; Sean Troth; Daniel J Holder; David Gerhold; Dina Andrews-Cleavenger; William Baer; Graham Betton; Denise Bounous; Kevin Carl; Nathaniel Collins; Peter Goering; Federico Goodsaid; Yi-Zhong Gu; Valerie Guilpin; Ernie Harpur; Alita Hassan; David Jacobson-Kram; Peter Kasper; David Laurie; Beatriz Silva Lima; Romaldas Maciulaitis; William Mattes; Gérard Maurer; Leslie Ann Obert; Josef Ozer; Marisa Papaluca-Amati; Jonathan A Phillips; Mark Pinches; Matthew J Schipper; Karol L Thompson; Spiros Vamvakas; Jean-Marc Vidal; Jacky Vonderscher; Elizabeth Walker; Craig Webb; Yan Yu
Journal:  Nat Biotechnol       Date:  2010-05-10       Impact factor: 54.908

3.  Experimental therapeutics: a paradigm for personalized medicine.

Authors:  Scott A Waldman; Walter K Kraft; Timothy J Nelson; Andre Terzic
Journal:  Clin Transl Sci       Date:  2009-12       Impact factor: 4.689

4.  Pharmacogenomics, evidence, and the role of payers.

Authors:  P A Deverka
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

5.  Bionic technologies transforming the science of healthcare delivery.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2011-04       Impact factor: 4.689

6.  Bridging the gap: moving predictive and prognostic assays from research to clinical use.

Authors:  P Michael Williams; Tracy G Lively; J Milburn Jessup; Barbara A Conley
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

Review 7.  Molecular staging individualizing cancer management.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  J Surg Oncol       Date:  2012-04-01       Impact factor: 3.454

Review 8.  GUCY2C molecular staging personalizes colorectal cancer patient management.

Authors:  Jian P Gong; Stephanie Schulz; Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

9.  An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights from the HPV Vaccine in Canada.

Authors:  Ana Komparic; Maxwell J Smith; Alison Thompson
Journal:  Public Health Ethics       Date:  2015-01-29       Impact factor: 1.940

Review 10.  Guanylyl cyclase C as a biomarker in colorectal cancer.

Authors:  Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.